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Background: Antiretroviral therapy (ART) is lifesaving for HIV-infected tuberculosis (TB) patients. ART-use by these
patients lag behind compared to HIV-testing and co-trimoxazole preventive therapy. TB programmes provide the
data on ART-use by HIV-infected TB patients, however often the HIV services provide the ART. We evaluated
whether the data on ART-use in the TB register were complete and correct. The timing of ART initiation was
evaluated to assess whether reporting on ART-use could have happened with the TB case finding reporting. We
collected data on TB treatment, HIV testing and ART for adult TB cases in 2007 from three TB clinics in Manica
Province, Mozambique. These data on use of ART from TB registers were compared with those from the HIV
services.
Findings: Of 628 patients included, 504 (81%) were tested and of these 356 (71%) were HIV-infected. Of the
co-infected patients, 81% registered with the HIV services in the same facility. The TB register was correct on
ART-use in 73% of co-infected cases and complete in 74%. Information on ART-use could have been reported with
the TB case finding reports in 56% of co-infected patients.
Conclusion: The TB register is reasonably correct and complete on ART-use. However, the HIV patient record seems
a much better source to provide this information. Reporting on ART-use at the end of the quarter in which TB
treatment starts provides the programme with timely but incomplete information. A more complete but less timely
picture is available after a year.
Keywords: Africa, Routine programme data, Tuberculosis, HIVBackground
The use of the potentially life saving antiretroviral therapy
(ART) for tuberculosis (TB) patients co-infected with the
Human Immunodeficiency Virus (HIV) did not progress
as much as would be necessary in addressing the dual TB
and HIV epidemic. Globally, the HIV prevalence among
new TB patients is 13%. In Mozambique this figure is 61%
[1]. Worldwide, 29% of co-infected patients used ART in
2005, which had increased to 46% in 2010. In the same
period, the percentage of TB patients knowing their HIV-
status increased fourfold and provision of co-trimoxazole
preventive therapy (CPT) reached 75% of HIV-infected
TB patients.* Correspondence: brouwer.miranda@gmail.com
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reproduction in any medium, provided the orThe World Health Organization (WHO) reports these
figures yearly in its global TB-control report. Although
in many countries the HIV services provide ART, also to
TB patients, national tuberculosis programmes (NTPs)
provide the data for this report. However, it is not
known how complete and correct the data on ART-use
are within NTPs. This is relevant as access to ART is
one of the main indicators of TB-HIV collaborative ac-
tivities [2].
To use routine programme data to monitor progress on
implementation, ideally the data are correct, complete
and timely available [3]. WHO recommends reporting of
HIV-testing for TB patients with the TB case finding data
at the end of the quarter [4]. Data are thus available
shortly after the end of the quarter. However, for CPT and
ART-use the recommendation is to report with the treat-
ment outcome data 12 months after the start of TBl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Brouwer et al. BMC Research Notes 2013, 6:23 Page 2 of 5
http://www.biomedcentral.com/1756-0500/6/23treatment. This is not timely reporting and precludes a
timely response from the programme in case of under-
utilization.
In Mozambique TB treatment staff offer HIV-testing
to all TB patients and CPT to the co-infected since
2006. For further care and treatment including ART,
they refer the co-infected patients to the HIV services.
TB staff report both HIV testing of TB patients, and
CPT and ART-use by the co-infected together with the
TB case finding data at the end of the quarter. Therefore
the data on CPT and ART-use are earlier available to the
programme in comparison to the WHO recommended
reporting timeline. This early availability can be useful
for programme management purposes if the data are
correct and complete.
This study therefore evaluated the correctness and
completeness of the routine TB registers on ART-use
among HIV-infected TB patients. We addressed the fol-
lowing questions: 1) How correct and complete are the
data in the TB register on ART-use? 2) How complete
could the data on ART-use be for reporting at the end
of the case finding quarter?Methods
Study design and setting
We selected purposefully three health facilities in Manica
province, Mozambique. Criteria for selection included
at least 150 TB patients notified in 2007 and the pres-
ence of both TB and HIV treatment services in the
same facility. The participating health facilities were an
urban facility in the provincial capital and two rural fa-
cilities about 20 and 80 kilometres from the provincial
capital.
In the TB recording and reporting system of Mozambique
all TB cases receive a unique number in the notifying facil-
ity’s TB register. Patients have their HIV test result and the
start date of ART recorded in this register. All patients
registered at the HIV clinic have a patient record, which
contains clinical information, and a unique number for
identification purposes. A link between the TB register and
HIV patient record does not exist. The unique HIV patient
number is not systematically recorded in the TB register,
though TB staff is encouraged to do so. The three selected
health facilities have, in addition to the government’s paper
recording system, an electronic HIV patient database in-
stalled by an international non-governmental organisation.Data collection
We included all notified TB cases aged 15 years and
older from January 1st until December 31st, 2007 from
the participating facilities. The facility’s TB supervisor
collected the data using standardized forms. Firstly, data
from the TB register were collected. These included: thestart date of TB treatment, the HIV test result and initi-
ation date of ART if the patient used ART.
Next, we used the unique HIV patient number, if avail-
able in the TB register, to identify the HIV records of
the HIV-positive TB patients. In addition, local staff fa-
miliar with the patients identified some records. If these
methods did not lead to identification of the HIV patient
record, we performed a search in the electronic HIV-
database using the patient’s name and age taken from
the TB register. We took the unique HIV patient num-
ber from the electronic database and used it to locate
the HIV patient record for positive matches. We limited
the identification of the HIV patient record to those
HIV-positive TB patients referred to the HIV services in
the same health facility.
We collected CD4+ cell count results and dates from
12 weeks before and during TB treatment, ART-use, and
the start date for ART from the HIV patient record.
To evaluate whether the TB register was correct and
complete on ART-use, we compared the data on ART-use
from the TB register with those of the HIV patient record.
In case of discrepancy on ART-use, we took the data from
the HIV patient record as correct for assessing ART-use
because the HIV services provide ART. We also verified if
the patient should have started ART according to the na-
tional guidelines for those co-infected patient not on
ART. At the time of the study, co-infected patients were
eligible for ART when their CD4+ count equalled or was
below 350 cells/mm3 [5]. We limited our analysis to the
patients for whom both the TB register information and
the HIV patient record were available.
We evaluated whether the patient started ART before
or in the same quarter as TB was diagnosed to assess
how complete the data could be at the end of the TB
case finding quarter.
We used standard WHO treatment outcomes to de-
fine the end of TB treatment [6]. This was necessary to
determine whether the patient initiated ART during the
course of TB treatment.
Statistical analysis
We used EpiData version 3.1 for data entry and performed
descriptive analysis with EpiData Analysis V2.2.1.171.
Ethics
The study protocol was approved by the National Bio-ethic
Committee of the Ministry of Health of Mozambique and
by the Institutional Review Board of the University of
Washington in Seattle, USA. Because we used routinely
available data, we did not obtain informed consent.
Findings
Between January 1st and December 31st, 2007, the three
health facilities notified 628 TB patients of 15 years and
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for which we identified the HIV patient records (n = 267).
Table 1 shows the TB-HIV data for the individual health
facilities.
Of 157 co-infected patients recorded in the TB-
register as using ART, 130 (83) were confirmed when
crosschecking the HIV patient record. Of the 110 co-
infected patients recorded in the TB register not to be
using ART, 64 (58%) were confirmed. In total, 194 (73%)
entries of ART-use in the TB-register were correct.
The HIV patient records had 176 patients recorded as
on ART. Of those, 130 patients had ART-use recorded
in the TB register, a completeness of 74%.
In addition to the 176 patients on ART in the HIV pa-
tient record, 23 patients not on ART should have been on
ART according to the national guidelines because they
had CD4+ cell counts equal to or below 350 cells/mm3
during or before TB treatment. In total, 199 co-infected
patients should have started or continued on ART whilst
on TB treatment. Of these 199 patients, 150 (75%) could
have been reported at the end of the quarter with the TB
notifications. Potentially, the information in the TB regis-
ter could have been complete for 150/267 (56%) at theFigure 1 Breakdown of notified TB patients and their linkage
to the HIV patient record.end of the TB case finding quarter. When reported with
the TB treatment outcomes, the TB register would have
been complete on ART-use for 199 of the 267 (75%) co-
infected patients.
Discussion
The data on ART-use in the TB register were correct in
73% and complete in 74%. The reporting at the end of
the case finding quarter could have been 56% complete,
if data on ART-use from the HIV patient records were
optimally transcribed in the TB registers.
The Global Fund to fight AIDS, Tuberculosis and Mal-
aria assesses performance of grants on their programmatic
achievements. The Global Fund considers a progress
against target achievement between 60 and 89% as ad-
equate [7]. Using this performance assessment, our study
showed that the information of the TB register on ART-
use had an adequate level.
However, there is much that can be improved in report-
ing on ART-use in co-infected patients. A reduction of
the incorrect recording of patients in the TB register as
using ART of whom ART-use was not confirmed by the
HIV patient record would improve data quality. In our
study we found this incorrect recording on ART-use in
17% of co-infected patients. We did not evaluate the
reasons for this. Anecdotal evidence informed us that
patients at times state they already use ART, whereas in
fact they do not. Reasons why patients do not state their
ART-use correctly might be even more complex than the
reasons why patients do not start ART. A recent qualita-
tive study in Malawi found that not starting ART was
related to both health system and patient reasons [8]. Rea-
sons in the former category included ART not being
offered and non-availability of ART drugs. Fear of drug
toxicity was the main patient related reason. The study
showed that to implement the recommendation to start
all co-infected patients on ART irrespective of the CD4+
cell count requires substantial efforts from the health sys-
tem [9]. A study in Cameroon explained a test rate of 95%
partly because patients usually follow health care provi-
ders’ recommendations [10]. This shows the importance
of the health care provider offering ART.
In addition, more improvement could come from
more complete recording of ART-use in the TB register.
This study showed that 26% of co-infected patients were
recorded in the TB register as not on ART but the HIV
patient recorded showed they were in fact using ART.
The NTP in Mozambique reported an ART-use of 33%
for the whole country in 2007 [11]. This was lower than
the 73% correctly recorded co-infected patients in the TB
register on ART that we found. We collected the data
more than 12 months after TB treatment started, whereas
the NTP data were reported at the end of the quarter
in which TB treatment started. This partly explains the
Table 1 Results of HIV testing, registration with HIV services and ART-use in the three health facilities
Facility A (Urban, in
provincial capital,
n = 153)
Facility B (Rural, 20 km from
provincial capital,
n = 245)





Number % Number % Number % Number %
HIV-test result in TB register 147 96 170 69 187 83 504 81
HIV-positive
(of those with HIV test result)
105 71 118 69 133 71 356 71
ART-use registered in TB register
(of the HIV-infected)
16 15 59 50 86 65 161 45
Registration with HIV services in the same
health facility (of the HIV-infected)
81 77 94 80 112 84 287 81
HIV Patient record available 74 91 83 88 110 98 267 93
ART-use in HIV patient record
(of the HIV-infected)
47 45 59 50 70 53 176 49
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provide ART and little collaboration or integration be-
tween the TB and HIV services existed. However, the
health facilities have an ART committee of which the TB
supervisor is a member. The committee discusses patients
that are about to start ART and as such the TB supervisor
potentially is aware of the ART status of the patient.
We found quite a difference between the individual
health facilities on HIV testing and on ART-use. It is not
clear where these differences come from. For HIV-test-
ing, stock outs of HIV-test kits could be a problem. The
urban health facility is close to the provincial distribution
centre and maybe suffers less from stock outs or for
a shorter period of time. The difference in ART-use
seemed much more related to the data exchange between
the two services. According to the TB register in facility
A, only 15% used ART, while the HIV-records showed a
use of 45%.
The reporting on ART-use at the end of the case find-
ing quarter was estimated to be complete in only 56%.
Reporting of ART-use with the TB treatment outcomes
12 months after the start of TB treatment increased
completeness to 75%, but reduces the timely availabili-
ty of information. Furthermore, in many countries the
reporting on treatment outcomes is limited to sputum
smear-positive cases whereas reporting on ART-use
would need to be for all HIV-infected TB cases. This
discrepancy may influence the quality of reporting on
ART-use. Electronic data systems could facilitate data
collection but also provide prompts to remind health
care providers to take certain action, for example to col-
lect a blood sample for a CD4+ cell count or to start
ART [12]. In our study 12% of the co-infected patients
did not have a single CD4+ cell count available during
TB treatment. Potentially more patient would have been
eligible to start ART.
Even though the data in the TB register on ART-use
were adequately correct and complete, this study showedthat services provided by one programme and reported
data on these services by another programme lead to in-
consistencies. Data reporting is not a goal on its own,
but provides programmes with essential information on
their performance. Ultimately, we want to improve pa-
tient outcome and integration of TB and HIV services
may be the answer to that. A recently published system-
atic review showed that integration of ART provision
into TB care seems to improve patients outcomes, how-
ever, the evidence is not yet sufficient [13].
Limitations
This was a retrospective study based on routine data. Se-
lection bias may have occurred by including only facil-
ities where both TB and HIV services were present in
one province in Mozambique. Potentially, ART-use may
be higher in facilities with both services available than in
facilities with only TB treatment and this may have led
to a potential overestimation of the ART-use.
Another source of selection bias might be that not all
HIV patient records could be traced. However, we have
no evidence to assume that the presence of an HIV-
record is associated with adequate reporting of data.
Furthermore, we may have underestimated the com-
pleteness of data because we did not verify ART status
of patients receiving ART in other health facilities than
the one where they were treated for TB.
We considered the information on ART-use from the
HIV patient record, partially from an electronic data-
base, as correct. Potentially the HIV patient record con-
tains incorrect data. However, a recent study from the
same study area validated the electronic database used
in our study [14]. That study found high levels of more
than 95% agreement for the CD4+ cell count, the date of
the CD4+ cell count and the start date of ART.
We collected the data 18 to 30 months after the start
of TB treatment. The WHO recommended reporting on
ART-use, is 12 months after the start of TB treatment.
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pleteness though we think that little incentive exists for
TB staff to update their registers after reporting the
treatment outcomes.
Conclusion
The data on ART-use in TB register are reasonably correct
and complete. However, the TB register may not be the best
source to report on ART-use during TB treatment because
the information in the HIV patient record is much more
accurate. Reporting on ART-use at the end of the quarter
in which TB treatment starts provides the programme with
timely but incomplete information. A more complete but
less timely picture is available after a year.
Future research should focus on how to use optimally
the available data in a way that does not add an extra
burden to health care workers.
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